WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H576769
CAS#: 276690-59-6
Description: Iroxanadine hydrochloride is a MAPK p38 inhibitor potentially for the treatment of atherosclerosis.
Hodoodo Cat#: H576769
Name: Iroxanadine hydrochloride
CAS#: 276690-59-6
Chemical Formula: C14H21ClN4O
Exact Mass: 296.14
Molecular Weight: 296.800
Elemental Analysis: C, 56.66; H, 7.13; Cl, 11.94; N, 18.88; O, 5.39
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Iroxanadine hydrochloride; Iroxanadine HCl
IUPAC/Chemical Name: 2H-1,2,4-Oxadiazine, 5,6-dihydro-5-(1-piperidinylmethyl)-3-(3-pyridinyl)-, monohydrochloride, (-)-
InChi Key: AVKGCNAECFSXHH-UHFFFAOYSA-N
InChi Code: 1S/C14H20N4O.ClH/c1-2-7-18(8-3-1)10-13-11-19-17-14(16-13)12-5-4-6-15-9-12;/h4-6,9,13H,1-3,7-8,10-11H2,(H,16,17);1H
SMILES Code: Cl.C(C1CONC(=N1)c2cccnc2)N3CCCCC3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 296.80 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Denes L, Bori Z, Csonka E, Entz L, Nagy Z. Reverse regulation of endothelial cells and myointimal hyperplasia on cell proliferation by a heatshock protein-coinducer after hypoxia. Stroke. 2008 Mar;39(3):1022-4. doi: 10.1161/STROKEAHA.107.495754. PubMed PMID: 18239173.
2: Kabakov AE, Budagova KR, Malyutina YV, Latchman DS, Csermely P. Pharmacological attenuation of apoptosis in reoxygenated endothelial cells. Cell Mol Life Sci. 2004 Dec;61(24):3076-86. PubMed PMID: 15583868.
3: Denes L, Entz L, Jancsik V. Restenosis and therapy. Int J Vasc Med. 2012;2012:406236. doi: 10.1155/2012/406236. PubMed PMID: 22489270; PubMed Central PMCID: PMC3303576.
4: Dénes L, Jednákovits A, Hargitai J, Pénzes Z, Balla A, Tálosi L, Krajcsi P, Csermely P. Pharmacologically activated migration of aortic endothelial cells is mediated through p38 SAPK. Br J Pharmacol. 2002 Jun;136(4):597-603. PubMed PMID: 12055138; PubMed Central PMCID: PMC1573374.
